

Table 1. General characteristics and CHOP-intend score evolution of the 17 patients

	med [Q1;Q3]	(min;max)
Male/Female (<i>n</i>, %)	10/7 (59)	
Age at onset (<i>months</i>)	2 [2;4]	(1;6)
Age at diagnosis (<i>months</i>)	4 [3;8]	(2;11)
Number of <i>SMN2</i> copies (<i>n</i>)	2 [2;3]	(2;3)
Age at first Nusinersen dose (<i>months</i>)	4 [3;9]	(2;29)
Number of Nusinersen doses (<i>n</i>)	9 [6.75;10]	(4;11)
CHOP INTEND at baseline (<i>n</i>=8)	27 [19.5;28.5]	(17;33)
CHOP INTEND at the end of the study (<i>n</i>=8)	46 [31;55.5]	(26;64)

Results are expressed as median, interquartile range: med [Q1;Q3]; minimum and maximum (min;max).